Inhibition of FGF/FGFR signaling is a promising strategy for the treatment of malignances dependent from FGF stimulation, including multiple myeloma (MM). The steroidal derivative NSC12 (compound 1) is a pan-FGF trap endowed with antitumor activity in vivo. Chemical modifications of compound 1 were explored to investigate structure-activity relationships, focusing on the role of the bis(trifluoromethyl)1,3-propanediol chain, the stereochemistry at C20 and functionalization of C3 position. Our studies unveiled compound 25b, the pregnane 3-keto 20R derivative of compound 1 as an effective agent, blocking the proliferation of MM cells in vitro by inhibiting FGF-dependent receptor activation and slowing MM growth in vivo. Importantly, the absence of the hydroxyl group at C3 prevents binding to estrogen receptors, which might concur to the antitumor activity observed for compound 1, leading to a specific FGF/FGFR system inhibitor, and further supporting the role of FGFR in anticancer therapy in MM.

Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma / Castelli, R.; Taranto, S.; Furiassi, L.; Bozza, N.; Marseglia, G.; Ferlenghi, F.; Rivara, S.; Retini, M.; Bedini, A.; Spadoni, G.; Matarazzo, S.; Ronca, R.; Presta, M.; Mor, M.; Giacomini, A.. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - 221:(2021), p. 113529.113529. [10.1016/j.ejmech.2021.113529]

Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma

Castelli R.;Bozza N.;Marseglia G.;Ferlenghi F.;Rivara S.
;
Mor M.;Giacomini A.
2021-01-01

Abstract

Inhibition of FGF/FGFR signaling is a promising strategy for the treatment of malignances dependent from FGF stimulation, including multiple myeloma (MM). The steroidal derivative NSC12 (compound 1) is a pan-FGF trap endowed with antitumor activity in vivo. Chemical modifications of compound 1 were explored to investigate structure-activity relationships, focusing on the role of the bis(trifluoromethyl)1,3-propanediol chain, the stereochemistry at C20 and functionalization of C3 position. Our studies unveiled compound 25b, the pregnane 3-keto 20R derivative of compound 1 as an effective agent, blocking the proliferation of MM cells in vitro by inhibiting FGF-dependent receptor activation and slowing MM growth in vivo. Importantly, the absence of the hydroxyl group at C3 prevents binding to estrogen receptors, which might concur to the antitumor activity observed for compound 1, leading to a specific FGF/FGFR system inhibitor, and further supporting the role of FGFR in anticancer therapy in MM.
2021
Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma / Castelli, R.; Taranto, S.; Furiassi, L.; Bozza, N.; Marseglia, G.; Ferlenghi, F.; Rivara, S.; Retini, M.; Bedini, A.; Spadoni, G.; Matarazzo, S.; Ronca, R.; Presta, M.; Mor, M.; Giacomini, A.. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - 221:(2021), p. 113529.113529. [10.1016/j.ejmech.2021.113529]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2902218
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact